The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | FLT3-mutated AML data at ASH 2021
Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, comments on FLT3-mutated acute myeloid leukemia (AML) data to be presented at the upcoming ASH 2021 Annual Meeting. Dr Röllig highlights a Phase III randomized study (NCT03182244) of gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed or refractory AML. The trial of over 200 patients demonstrated that gilteritinib significantly improved overall survival and event-free survival compared with salvage chemotherapy, validating previous data from the ADMIRAL trial. Dr Röllig also discusses the Phase 3 LACEWING trial (NCT02752035) of gilteritinib plus azacitidine compared to azacitidine alone in FLT3-mutated AML. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
